Diltiazem long-acting (Apo-Diltiazem): Brand change

Brand change Active

Supply is ending for all strengths of Apo-Diltiazem brand long-acting diltiazem. We have secured alternatives for all 3 presentations.

120mg capsules – Accord (section 29)

We have secured a short-term supply of Accord brand 120 mg diltiazem hydrochloride capsules. It will be listed from 1 December 2021. 

This brand is not Medsafe approved, it will need to be prescribed and supplied in line with section 29 of the Medicines Act.

Prescribing and supplying a medicine under section 29

Section 29 of the Medicines Act allows for medicines that are not Medsafe approved to be prescribed and supplied to people. The medicine must be prescribed by someone registered with the Medical Council of New Zealand – such as doctors. 

We know supplying a medicine under section 29 is not ideal. In this case, however, the alternative would be for patients to have no 120mg presentation of long-acting diltiazem. 

We apologise for any inconvenience this causes. 

Prescriber and pharmacist requirements for section 29 medicines – Medsafe website(external link)

What patients need to know about section 29 medicines – Health Navigator website(external link)

180mg and 240mg capsules long-acting diltiazem

We listed Cardizem CD brand long-acting 180mg and 240mg diltiazem capsules on 1 October 2021. Apo-Diltizem CD will be delisted from the Schedule on 1 February 2022. 

We consulted on this decision on in February 2021. We appreciated the feedback we received. You can read the full decision and a discussion of the feedback we received on our website.

Decision to secure supply of 180 mg and 240 mg diltiazem hydrochloride capsules

Check the Schedule listing for pharmacodes(external link)

Thank you

We appreciate the time and effort of pharmacists and other health care professionals to support patients through brand changes for medicines.

Who to contact

Information about the discontinuation of immediate release diltiazem is also on our website, read the Dilzem discontinuation notice

If you have questions about the funding for diltiazem, email enquiry@pharmac.govt.nz